0000000001107600
AUTHOR
Marta Palop-cervera
showing 2 related works from this author
Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study
2021
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …
sj-pdf-1-ajr-10.1177_1945892420972326 - Supplemental material for Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and M…
2020
Supplemental material, sj-pdf-1-ajr-10.1177_1945892420972326 for Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study by Miguel Armengot-Carceller MD, PhD María José Gómez-Gómez MD, PhD Carmen García-Navalón MD Encarna Doménech-Campos Muñoz- Noelia Fernández MD, PhD MD, PhD Ainhoa García-Lliberós de Miguel MD, PhD Jaime Marco-Algarra MD, PhD Marta Palop-Cervera MD Alfonso García Piñero MD, PhD in American Journal of Rhinology & Allergy